<!-- .entry-meta -->
<div class="entry-content">
<p><a href="https://economicprism.com/welcome-to-life-after-the-end-of-the-world/"><img decoding="async" class="alignleft size-full wp-image-2253" title="Welcome to Life After the End of the World" alt="" src="https://economicprism.com/wp-content/uploads/2012/12/MayanPyramid.jpg" width="150" height="150"/></a>“It’s crucial to save the frog.” – Al Gore Jr., Nobel Prize Laureate.</p>
The Great Deceivers of Our Era
The unknowns in our lives can be quite disconcerting. People often spend substantial amounts of money seeking assurance from well-versed individuals who predict the future. The accuracy of their forecasts is secondary to their persuasive delivery.
Imagine a scenario where a civil engineer made as many errors in judgment as a weather forecaster, or where a carpenter was consistently as unreliable as a stockbroker. Such inaccuracies could lead to catastrophic outcomes—bridges crumbling and roofs collapsing just as a storm rolls in or a market takes a downturn.
In today’s society, central bankers have emerged as the great deceivers. Consider Fed Chairman Ben Bernanke, for example, who is directing the printing of $85 billion each month to support U.S. Treasury debt and the mortgage market.
According to Bernanke, these monetary strategies are in our best interest. He argues that the economy suffers from insufficient demand. His belief is that making credit more accessible will spark demand, thereby stimulating the economy and reducing unemployment rates. Continue reading
<!-- .entry-utility -->
</div><div id="post-2245">
<!-- .entry-meta -->
<div class="entry-content">
<p><a href="https://economicprism.com/breaking-down-a-biotech-winner/"><img decoding="async" class="alignleft size-full wp-image-885" title="Breaking Down a Biotech Winner" alt="" src="https://economicprism.com/wp-content/uploads/2011/12/Economy.gif" width="150" height="150"/></a>Breaking Down a Biotech Winner<br/>By Alex Daley, <a onclick="javascript:pageTracker._trackPageview('/outgoing/www.caseyresearch.com/go/bv9hE/GDO');" href="http://www.caseyresearch.com/go/bv9hE/GDO" target="_blank">Casey Extraordinary Technology </a></p>
Conventional cancer treatments generally rely on a harsh combination of surgery, radiation, and chemotherapy—often referred to as “slash, burn, and poison.” However, innovative treatments currently being developed in laboratories around the globe hold the promise of moving beyond these methods; there has been no other illness that has attracted as much research interest and funding in the field of modern biotechnology over the past thirty years.
Though I won’t delve into all those possible breakthroughs here, it’s worth noting that while many will likely succeed and enrich numerous investors over the coming decades, a considerable number will not succeed. Furthermore, even those that do may take years to deliver significant returns for their investors.
That said, one burgeoning company has developed a groundbreaking approach to cancer treatment that shows considerable promise. Featured in a recent edition of *Casey Extraordinary Technology*, this company has already yielded a remarkable 167 percent gain for its subscribers within a mere six-month span, suggesting that it may generate substantial profits for investors in the future. Continue reading